EUVIMEDEUVIMED entdecken
Crossref

Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series

Tao Pan, Hui Yang, Wu-Yi Wang, Yuan-Yi Rui, Zi-Jian Deng, Yung-Chang Chen, Chao Liu, Hai Hu

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2024.01.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Tao Pan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Colorectal Cancer Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Aff…. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Brain Neoplasms, Neoplastic Syndromes, Hereditary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Sichuan Province Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Although ipilimumab plus nivolumab have significantly improved the survival of metastatic colorectal cancer (CRC) with mismatch repair deficient (dMMR) /microsatellite instability-high (MSI-H), the data on neoadjuvant setting is limited. PATIENTS AND METHODS: We enrolled 11 patients with advanced dMMR/MSI-H CRC. 10 patients were locally advanced and 1 was metastatic. Ten patients were treated with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg), and 1 patient was treated with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg) with 2 cycles. All the patients underwent surgery after immunotherapy. The aim of the study was to evaluate the safety and short-term efficacy of this strategy. RESULTS: Pathologic responses were observed in 11/11 (100%) dMMR/MSI-H tumors, with 9/11 (81.8%) achieving complete responses. Among these 9 cases with complete responses, 1 achieved a radiological noncomplete response after treatment with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg), so another cycle of treatment with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg) was administered, followed by surgery. The postoperative pathological evaluation was a complete response. Seven patients (63.6%) developed grade I/II adverse events. No patients developed grade III/IV adverse events or postoperative complications. CONCLUSION: Neoadjuvant immunotherapy with ipilimumab plus nivolumab induced tumor regression with a major clinical and pathological response in advanced dMMR/MSI-H CRC. Notably, patients do not achieve a complete response to neoadjuvant immunotherapy, additional neoadjuvant immunotherapy may offer benefits. Further research is needed to assess the long-term efficacy of this strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsColorectal NeoplasmsBrain NeoplasmsNeoplastic Syndromes, HereditaryHumansNivolumabIpilimumabNeoadjuvant TherapyMicrosatellite InstabilityDNA Mismatch RepairImmunotherapy

Stichwörter der Autor:innen

CTLA-4Colorectal cancerNeoadjuvant immunotherapyPD-1dMMR/MSI-H

Substanzen

NivolumabIpilimumab

Autor:innen und Institutionen

  • Department of Colorectal Cancer Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Techno…
  • Department of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of C…

Förderung

  • Sichuan Province Health Commission

Zitieren

APA

Pan, T., Yang, H., Wang, W. Y., Rui, Y. Y., Deng, Z. J., Chen, Y. C., Liu, C., & Hu, H. (2024). Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.01.002

Vancouver

Pan T, Yang H, Wang WY, Rui YY, Deng ZJ, Chen YC, et al. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.01.002

BibTeX
@article{Pan2024,
  author = {Pan, Tao and Yang, Hui and Wang, Wu-Yi and Rui, Yuan-Yi and Deng, Zi-Jian and Chen, Yung-Chang and Liu, Chao and Hu, Hai},
  title = {Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2024.01.002}
}
Kostenlos starten →